Bioventus (BVS) Share-based Compensation (2021 - 2026)

Bioventus (BVS) has 6 years of Share-based Compensation data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 35.21% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $13.5 million (up 6.5% YoY), and the FY2025 full-year result was $12.7 million, down 4.53% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.3 million, down from $3.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.8 million in Q2 2024 and bottomed at -$2.7 million in Q3 2023.
• The 5-year median for Share-based Compensation is $3.2 million (2025), against an average of $2.9 million.
• The widest annual swing landed in 2023, when Share-based Compensation tumbled 159.19%; it then soared 311.46% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $3.4 million in 2022, then sank by 48.28% to $1.8 million in 2023, then climbed by 13.58% to $2.0 million in 2024, then surged by 70.63% to $3.4 million in 2025, then dropped by 5.12% to $3.3 million in 2026.
• The last three Share-based Compensation figures came in at $3.3 million (Q1 2026), $3.4 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.

Peer Comparison